## AMENDMENTS TO THE CLAIMS

In the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-69: Canceled.

70. (Previously presented) The method of claim 73, wherein the step of contacting is performed in vitro.

71. (Previously presented) The method of claim 73, wherein the step of contacting is performed in vivo.

72. (Previously presented) The method of claim 73, wherein the B7-2 is human B7-2.

73. (Previously presented) A method for blocking binding interactions of B7-2 with CD28 or CTLA4 on an immune cell, comprising contacting the immune cell with an antibody that recognizes the polypeptide shown in SEQ ID NO:2 to thereby block the binding interactions of B7-2 with the CD28 or CTLA4 on the immune cell.

74. (Previously presented) The method of claim 73, wherein the antibody is a polyclonal antibody.

75. (Previously presented) The method of claim 73, wherein the antibody is a monoclonal antibody.

76. (Previously presented) The method of claim 73, wherein the antibody is a chimeric antibody.

77. (Previously presented) The method of claim 73, wherein the antibody is a humanized antibody.

78. (Previously presented) The method of claim 73, wherein the antibody is a human antibody.

79. (Previously presented) The method of claim 73, wherein the antibody is a $F(ab')_2$ or an Fab' fragment.

80. (Previously presented) The method of claim 73, wherein the antibody is produced by a hybridoma selected from the group consisting of: ATCC accession number HB 11688, ATCC accession number HB 11687, and ATCC accession number HB 11686.

81. (Previously presented) A method for inhibiting proliferation of a T cell comprising contacting a cell bearing B7-2 an antibody that recognizes the polypeptide shown in SEQ ID NO:2 to thereby inhibit the proliferation of the T cell.

82. (Previously presented) The method of claim 81, wherein the step of contacting is performed in vitro.

83. (Previously presented) The method of claim 81, wherein the step of contacting is performed in vivo.

84. (Previously presented) The method of claim 81, wherein the B7-2 is human B7-2.

85. (Previously presented) The method of claim 81, wherein the antibody is a polyclonal antibody.

86. (Previously presented) The method of claim 81, wherein the antibody is a monoclonal antibody.

87. (Previously presented) The method of claim 81, wherein the antibody is a chimeric antibody.

88. (Previously presented) The method of claim 81, wherein the antibody is a humanized antibody

89. (Previously presented) The method of claim 81, wherein the antibody is a human antibody.

90. (Previously presented) The method of claim 81, wherein the antibody is a $F(ab')_2$ or an Fab' fragment.

91. (Previously presented) The method of claim 81, wherein the antibody is produced by a hybridoma selected from the group consisting of: ATCC accession number HB 11688, ATCC accession number HB 11687, and ATCC accession number HB 11686.

92. (Previously presented) The method of claim 81, further comprising contacting the cell with an additional immunosuppressive agent.

93. (Previously presented) A method for inhibiting cytokine production by a T cell comprising contacting a cell bearing B7-2 with an antibody that recognizes the polypeptide shown in SEQ ID NO:2, thereby inhibiting cytokine production by the T cell.

94. (Previously presented) The method of claim 93, wherein the step of contacting is performed in vitro.

95. (Previously presented) The method of claim 93, wherein the step of contacting is performed in vivo.

96. (Previously presented) The method of claim 93, wherein the B7-2 is human B7-2.

97. (Previously presented) The method of claim 93, wherein the antibody is a polyclonal antibody.

98. (Previously presented) The method of claim 93, wherein the antibody is a monoclonal antibody.

99. (Previously presented) The method of claim 93, wherein the antibody is a chimeric antibody.

100. (Previously presented) The method of claim 93, wherein the antibody is a humanized antibody

101. (Previously presented) The method of claim 93, wherein the antibody is a human antibody.

102. (Previously presented) The method of claim 93, wherein the antibody is a $F(ab')_2$ or an Fab' fragment.

103. (Previously presented) The method of claim 93, wherein the antibody is produced by a hybridoma selected from the group consisting of: ATCC accession number HB 11688, ATCC accession number HB 11687, and ATCC accession number HB 11686.

104. (Previously presented) The method of claim 93, further comprising contacting the cell with an additional immunosuppressive agent.

105. (Previously presented) A method for downregulating an immune response comprising administering an antibody that recognizes the polypeptide shown in SEQ ID NO:2 to a subject, such that an immune response is downregulated.

106. (Previously presented) The method of claim 105, wherein the antibody is administered prophylactically.

107. (Previously presented) The method of claim 105, wherein the antibody is administered therapeutically.

108. (Previously presented) The method of claim 105, wherein the subject is a human subject.

109. (Previously presented) The method of claim 105, wherein the antibody is a polyclonal antibody.

110. (Previously presented) The method of claim 105, wherein the antibody is a monoclonal antibody.

111. (Previously presented) The method of claim 105, wherein the antibody is a chimeric antibody.

112. (Previously presented) The method of claim 105, wherein the antibody is a humanized antibody

113. (Previously presented) The method of claim 105, wherein the antibody is a human antibody.

114. (Previously presented) The method of claim 105, wherein the antibody is a $F(ab')_2$ or an Fab' fragment.

115. (Previously presented) The method of claim 105, wherein the antibody is produced by a hybridoma selected from the group consisting of: ATCC accession number HB 11688, ATCC accession number HB 11687, and ATCC accession number HB 11686.

116. Canceled.

117. Canceled.

118. Canceled.

119. (Previously presented) A method for blocking binding interactions of B7-2 with CD28 or CTLA4 on an immune cell, comprising contacting the immune cell with an antibody that recognizes the polypeptide shown in SEQ ID NO:23 to thereby block the binding interactions of B7-2 with the ligand on the immune cell.

120. (Previously presented) A method for inhibiting proliferation of a T cell comprising contacting the T cell with an antibody that recognizes the polypeptide shown in SEQ ID NO:23 to thereby inhibit the proliferation of the T cell.

121. (Previously presented) A method for inhibiting cytokine production by a T cell comprising contacting the T cell with an antibody that recognizes the polypeptide shown in SEQ ID NO:23, thereby inhibiting cytokine production by the T cell.